Morphine versus oxycodone analgesia after percutaneous kidney stone surgery
- 573 Downloads
According to previous studies oxycodone might have some advantages over morphine in the treatment of visceral pain. This study investigated the opioid consumption (primary outcome), pain relief and side effects (secondary outcomes) of morphine versus oxycodone after percutaneous nephrolithotomy using a method where the somatic pain component was minimized. Forty-four adult patients were studied. The patients were randomised to receive either morphine or oxycodone intravenously as postoperative pain treatment. During the first 4 h after surgery the opioid consumption, pain scores and side effects (nausea, dizziness, sedation, respiratory effects and itching) were registered. The postoperative opioid consumption varied considerably between the patients but the mean opioid consumption in the morphine and oxycodone group was comparable (18.93 mg versus 16.15 mg, P = 0.7). Nausea was significantly less frequent with morphine (P = 0.03). In this study morphine and oxycodone produced similar analgesia the first 4 h after surgery but the frequency of nausea was significantly less patient-reported with morphine. The hypothesis that oxycodone would be superior in the treatment of visceral pain after percutaneous kidney stone operation was not confirmed.
KeywordsMorphine Oxycodone Visceral pain Postoperative acute pain Kidney stone Percutaneous nephrolithotomy
The study was supported by an unrestricted grant from Norpharma A/S. Mech-Sense, Aalborg University Hospital has received funding from The Danish Council for Strategic Research. René dePont Christensen assisted with statistical support.
Conflict of interest
Asbjørn Mohr Drewes has received unrestricted research grants from Mundipharma, AstraZeneca, Lundbeck and Pfizer and served as a Consultant/Advisory Board member for Mundipharma, AstraZeneca, Almirall and Shire.
Palle Jørn Sloth Osther has received an unrestricted research grant from Norpharma A/S.
Anne Estrup Olesen and Katja Venborg Pedersen have no conflict of interest to declare.
- 22.Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L et al (2010) The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 24(4):517–524CrossRefPubMedGoogle Scholar